Table 1 Application of MSCs in preventing GVHD
N | Source of MSCs | Diseases | Median dose of MSCs (cells/kg) | Number of infusions | Time between first infusion and HCT | Outcome | Ref. |
|---|---|---|---|---|---|---|---|
33 | Bone marrow | AML/MDS: 23 ALL: 7 CML: 3 | 1 × 106 | – | 27士1.5 days after HCT | Incidence of aGVHD: 9.4% Relapse rate: 25% Graft rejection: 6.2% Death rate: 18.8% | [38] |
44 | Bone marrow | SAA: 31 VSAA: 13 | 3.6 × 108 | 2 | Within 6 h before HCT | Incidence of II–IV aGVHD: 29.3% Incidence of cGVHD: 14.6% 1-year OS: 77.3% | [42] |
20 | Bone marrow | AML: 7 NML:5 MM: 5 Other: 3 | – | 1 | 30–120 min before HCT | Incidence of aGVHD: 35% Incidence of cGVHD: 65% 1 year OS: 80% 1 year PFS: 60% | [43] |
17 | Bone marrow | PMF | 6.5 × 106 |  | The day of HCT 7 Days after HCT | Cumulative incidence of aGVHD: 62% Cumulative incidence of overall cGVHD at 2 years: 63% Cumulative incidence of moderate to severe cGVHD at 2 years: 17% | [44] , |
17 | Cord blood | SAA | 4 × 106 | 1 | 6 h before HCT | Incidence of III–IV aGVHD: 23.5% Incidence of cGVHD: 14.2% 3 month survival rates: 88.2% 6 month survival rates: 76.5% | [39] |
62 | Cord blood | AML: 43 ALL: 14 MDS: 5 | – | 3.7 | – | 2 year cumulative incidence of cGVHD: 27.4% 2 year OS: 66.1% | [41] |
77 | Cord blood | SAA or VSAA: 72 SAA& PNH: 5 | 5 × 105 | 1 | 4 h before HCT | Incidence of II–IV aGVHD: 18% Incidence of III–IV aGVHD: 10% Incidence of extensive cGVHD: 7% 1 year OS: 93.1% 5 year OS: 87.9% | [45] |